Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 3Neoplasms 2Hematologic Neoplasms 2Rare Diseases 1Neurologic Manifestations 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myasthenia Gravis 1Mental Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Infections 1Burkitt Lymphoma 1Agammaglobulinemia 1

Interventions

Metformin 2Leuprolide 2Collagenases 2Clomiphene 2tremelimumab 1durvalumab 1Temozolomide 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Propofol 1Prednisone 1Plasma Exchange 1Nivolumab 1Midazolam 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Infliximab 1Immunoglobulins 1High-Throughput Nucleotide Sequencing 1Fentanyl 1FANG vaccine 1Cyclophosphamide 1Clomipramine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rare Diseases × Immunoglobulins × Clear all
NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡